Albireo Pharma Inc

Albireo Pharma — Biodel — Merger or Acquisition (September 2016)

45 slides from Albireo Pharma's merger presentation, Sep 22, 2016

  1. Slide 1: Biodel Inc and Albireo Limited Share Exchange Agreement

    Biodel Inc and Albireo Limited Share Exchange Agreement NASDAQ: BIOD │ September 21, 2016 Exhibit 99.1

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Certain statements contained in this presentation regarding matters that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities L

  3. Slide 3: Additional Information and Where You Can Find It

    Additional Information and Where You Can Find It This presentation may be deemed to be solicitation material in respect of the proposed transaction between Biodel Inc. (Biodel), Albireo Limited (Albireo) and Albireo stockholders and noteholders. In connection with the proposed transaction, Biodel fi

  4. Slide 4: Biodel - Albireo Share Exchange Agreement

    Biodel - Albireo Share Exchange Agreement Follows Biodel’s extensive review of strategic alternatives All-stock transaction: Biodel to acquire all outstanding shares of Albireo in exchange for newly issued shares of Biodel common stock Biodel stockholders will own approximately 32.875% and Albireo a

  5. Slide 5: Biodel - Albireo Combination

    Biodel - Albireo Combination NASDAQ-listed company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, as well as chronic constipation, bile acid malabsorption disease and NASH Lead asset, A4250, is a first-in-class product candidate in Phase 2 developm

  6. Slide 6: Significant News Flow and Near-Term Milestones

    Significant News Flow and Near-Term Milestones Projected Event Projected Timing A4250: report additional pediatric data from ongoing Ph2 trial Q4 2016 A4250: FDA meeting (pre-Ph3) Q4 2016 Elobixibat: report data from ongoing Ph3 Trial in Japan 2H 2016 Elobixibat: JNDA filing Q1 2017 A4250: report da

  7. Slide 7: Biodel - Albireo Leadership

    Combined company will be led by an experienced management team associated with multiple successful NDAs/EMAs and marketed products Ron Cooper – President and CEO Former President of Europe, Bristol-Myers Squibb Board to be comprised of seven directors, five from Albireo and two from Biodel David Chi

  8. Slide 8: Hope for Children with Orphan Liver Diseases Through Bile Acid Modulation

    Hope for Children with Orphan Liver Diseases Through Bile Acid Modulation

  9. Slide 9: Albireo: Innovative Science + Deep Pipeline + Experienced Management

    Albireo Innovative Science + Deep Pipeline + Experienced Management Leader in the development of bile acid modulators to treat liver and GI diseases Three clinical assets, including lead Phase 2 orphan product candidate and Phase 3 constipation product candidate Multiple near-term inflection opportu

  10. Slide 10: Experienced Management Team

    Jan Mattsson, PhD Chief Operating Officer (Co-founder) AstraZeneca Tom Shea Chief Financial Officer Cubist, Euthymics, Neurovance, EBI, Tolerx, Epirus Pete Zorn SVP, Corporate Development and General Counsel Santaris, Targacept Deep Biotech and Pharma Experienced Management Team Paresh Soni MBChB, F

  11. Slide 11: A Robust Pipeline Targeting Liver and GI Diseases and Disorders

    A Robust Pipeline Targeting Liver and GI Diseases and Disorders Phase 1 Preclinical Phase 2 Phase 3 Lead Program: Other Rare Pediatric Liver Diseases Ped. study ongoing; additional data expected 4Q 2016 Orphan GI Indication PPAR agonists Inflammatory Bowel Diseases NK antagonist Preclinical Programs

  12. Slide 12: Pediatric Orphan Opportunities Provide Foundation for Albireo Thesis

    Pediatric Orphan Opportunities Provide Foundation for Albireo Thesis Primary Focus Elobixibat partnering in Japan provides potential nondilutive capital to support programs A4250 Novel, First-in-Class Product Candidate to Treat Multiple Pediatric Orphan Liver Diseases with No Approved Drug Options P

  13. Slide 13: A4250 for Orphan Pediatric Liver Diseases

    A4250 for Orphan Pediatric Liver Diseases

  14. Slide 14: Positioned to Become First Drug Approved for PFIC

    Positioned to Become First Drug Approved for Progressive Familial Intrahepatic Cholestasis A4250 The market opportunity… Multiple pediatric orphan liver diseases and disorders with no approved drugs; lifetime treatment The science… Elevated serum bile acids linked to both progressive liver disease a

  15. Slide 15: Inhibits Bile Acid Re-uptake from the Intestine to Reduce Bile Acids in the Liver

    Inhibits Bile Acid Re-uptake from the Intestine to Reduce Bile Acids in the Liver A4250 ~ 95% of bile acids (BA) pumped from small intestine to liver, IBAT key mediator Inhibitors selectively reduce BA re-uptake and increase colonic BA Reduced liver and serum bile acids to treat cholestatic liver di

  16. Slide 16: Estimated ~10,000 PFIC Patients in Major Drug Markets

    Estimated ~10,000 PFIC Patients in Major Drug Markets No Approved Drug Options for PFIC A4250 PFIC-1 ATP8B1 gene (FIC1) affects BSEP expression + function Liver, small intestine, bladder, stomach, pancreas PFIC-2 ABCB11 gene, BSEP pump clears BA from hepatocyte Double truncating mutation can cause h

  17. Slide 17: Benefits of Bile Diversion Surgery Supports Rationale for IBAT Inhibition

    Benefits of Bile Diversion Surgery Supports Rationale for IBAT Inhibition to Treat PFIC A4250 Before Surgery One Year After Surgery Bile Acids (umol/L) 337 11 Bilirubin (umol/L) 41 25 Itching (0-5) 3 1 Long-term benefits of PEBD include sustained reduction in cholestasis and fibrosis (Arnell, et al.

  18. Slide 18: Preclinical and Early Clinical Data Provide Proof of Principle and Mechanism

    Preclinical and Early Clinical Data Provide Proof of Principle and Mechanism 2 weeks 4 weeks ALP (U/L) 0 50 100 150 200 250 300 * 350 * ALT (U/L) 0 200 400 600 800 * 1000 2 weeks 4 weeks ALT: alanine aminotransferase ALP: alkaline phosphatase Preclinical Cholestatic Liver Disease Model ↓ Liver Enzym

  19. Slide 19: Serum and Fecal Bile Acid Data Support Phase 2 Dosing

    Phase 1 Serum and Fecal Bile Acid Data Support Phase 2 Dosing A4250 Therapeutic benefit and tolerability within projected dose range 1 mg A4250 3 mg A4250 Blockage of IBAT achieved with therapeutic benefit and no diarrhea Blockage of IBAT achieved with therapeutic benefit and mild diarrhea in 3 of 6

  20. Slide 20: Study in Adults with PBC to Support Pediatric Development

    Study in Adults with PBC to Support Pediatric Development First Cohort Data Shows Dramatic Effect on Pruritus Investigator-Initiated Ph2 Primary Biliary Cholangitis study Crossover design, 3x4 weeks treatment (cholestyramine x A4250 x cholestyramine) 1.5mg A4250 QD for 1 wk + 3mg A4250 QD for 3 wks

  21. Slide 21: Ongoing Phase 2 Study in Pediatric Cholestatic Liver Disease

    Ongoing Phase 2 Study in Ped. Chol. Liver Disease Designed to Support Pivotal Development in PFIC Key inclusion criteria Diagnosis of pruritus due to chronic cholestasis (e.g., PFIC, Alagille syndrome (ALGS), primary sclerosing cholangitis (PSC), Biliary Atresia) Serum total bile acids ≥ 2x upper li

  22. Slide 22: Ph2 Pediatric Study: Outline

    Ph2 Pediatric Study: Outline * Wash-out in case of bile acid resin or other prohibited medication use of 7 days required PK A4250

  23. Slide 23: Ph2 Pediatric Study: Patient Demographics and Dose Summary

    A4250 Ph2 Pediatric Study: Patient Demographics and Dose Summary Cohort (mg/kg) Country Gender Age Dose (mg) Diagnosis 0.01 Sweden M 15 0.52 Alagille Denmark M 9 0.30 Alagille France F 9 0.24 Mixed Cholestasis Germany M 6 0.17 Alagille 0.03 Germany F 2 0.35 Biliary Atresia France F 4 0.45 PFIC-2 Fra

  24. Slide 24: Ph2 Pediatric Study: Pre-study Hypothesis for Cohorts 1-3

    Ph2 Pediatric Study: Pre-study Hypothesis for Cohorts 1-3 Cohort One (0.01 mg/kg), Two (0.03 mg/kg), Three (0.06 mg/kg) A4250 Safety and Tolerability No serious adverse events, good tolerability, low systemic exposure Potential diarrhea to appear somewhere in Cohorts 3-6 based on prior adult data Ef

  25. Slide 25: Ph2 Pediatric Study: Favorable Safety and Tolerability Data

    Ph2 Pediatric Study: Favorable Safety and Tolerability Data A4250 Primary Safety Endpoint No treatment-emergent serious adverse events (SAE) Adverse Events No dropouts Adverse events generally mild and transient No AEs in 4-week dosing period deemed by investigator to be likely drug related A single

  26. Slide 26: Ph2 Pediatric Study: Positive Effects Shown, Particularly in Highest Dose Cohort

    A4250 Ph2 Pediatric Study: Positive Effects Shown, Particularly in Highest Dose Cohort Completed Measure Cohort 1 0.01mg/kg Cohort 2 0.03mg/kg Cohort 3 0.06mg/kg Mean Dose 0.3 mg 0.7 mg 1.4 mg Mean % Change from Baseline Serum Bile Acids (primary efficacy endpoint) -31% ± 23 -45% ± 16 -63% ± 12 Prur

  27. Slide 27: Ph2 Pediatric Study: Promising Safety and Efficacy Data

    A4250 Ph2 Pediatric Study: Promising Safety and Efficacy Data No SAEs Minimal systemic exposure Zero dropouts No AEs assessed as likely drug related Dose-related trend in reduction 63% mean reduction in highest dose cohort Favorable reductions/improvements overall Generally consistent across pruritu

  28. Slide 28: Staged Clinical Development Approach

    Staged Clinical Development Approach to Leverage Data and Maximize Product Opportunity and Value A4250 POC* in Adults (Primary Biliary Cirrhosis) Ph2 Cholestatic Liver Disease in Children Ph2 Primary Sclerosing Cholangitis PFIC Pivotal Alagille Syndrome Biliary Atresia Pruritus in Ped. Chol. Liver D

  29. Slide 29: Regulatory Strategy: Subpart H Approval for PFIC

    Regulatory Strategy: Subpart H Approval for PFIC with Post-Approval Long-Term Outcome Study Seek accelerated approval for PFIC treatment using surrogate endpoint Study planning ongoing; assessing serum bile acids, pruritus and sleep as endpoints following FDA discussions Long-term outcome study to b

  30. Slide 30: A4250 – Potent Compound with Dose Response

    A4250 – Potent Compound with Dose Response Sources: Graffner et al. Aliment Pharmacol Ther 2016 (A4250 data); Form S-1 Registration Statement of Lumena Pharmaceuticals filed April 2, 2014 (SHP625 data) Serum bile acids AUC 0-15h Day 14 A4250 Permanent cation IC50 (human) 0.28 nM No cation IC50 (huma

  31. Slide 31: Ph2 Outcomes with Shire IBATi Validate Mechanism

    Ph2 Outcomes with Shire IBATi* Validate Mechanism, Highlight Need for Superior Compound A4250 The Albireo Approach Potent Compound with Dose Response + Staged Development Strategy PFIC Did not meet 1° endpoint of SBA reduction; significant improvement in pruritus and normalized baseline elevated liv

  32. Slide 32: A Compelling Commercial Opportunity

    A Compelling Commercial Opportunity Pediatric Cholestatic Pruritus Biliary Atresia A4250 Attractive Orphan Pricing and Reimbursement Opportunity Multiple Rare Diseases with No Approved Drugs* Favorable Competitive Landscape Expected to Enable Strong Share Penetration *Estimated prevalence data deriv

  33. Slide 33: Pipeline Programs

    —f Pipeline Programs SBiopEL Albireo

  34. Slide 34: First and Only Large Bowel-Acting Agent for CIC

    First and Only Large Bowel-Acting Agent for CIC that Increases Both Secretion AND Motility The market opportunity… 156% dollar Rx market growth since 2011 (IMS Monthly NPA December 2014) The data… Strong US Ph2b efficacy data with favorable AE profile Ph2b results reproduced in Japan, leading to rap

  35. Slide 35: Unique Dual Impact and Site of Action Provides Commercial Differentiation

    Unique Dual Impact and Site of Action Provides Substantial Commercial Differentiation Action Product Mechanism Status Small intestinal secretory agent Lubiprostone (Amitiza®) Takeda/Mylan Chloride channel agonist Approved 2015 Sales ~$311M Small intestinal secretory agent Linaclotide (Linzess®) Iron

  36. Slide 36: Phase 3 Ongoing in Japan; Favorable US/EU Data Generated

    Phase 3 — Ongoing in Japan; Favorable US/EU Data Generated, Interaction with FDA for US Pivotal Program Underway Elobixibat Commercial Rights EA Pharma (Eisai/Ajinomoto)* Albireo (seeking partner) Data Ph2: n =163; met primary endpoint with high statistical significance Ph2: n=190; met primary endpo

  37. Slide 37: Positioned to Become First Drug Approved for Bile Acid Malabsorption Disease

    ** p < 0.01 * p < 0.05 Positioned to Become First Drug Approved for Bile Acid Malabsorption Disease The science… Designed to deliver cholestyramine directly to colon without affecting small intestine Earlier generation formulation proves principle in Ph2 by improving diarrhea and related measures (A

  38. Slide 38: NASH Platform: IBAT Inhibition Benefits Four Principal Hallmarks

    Reduction of Pro-Inflammatory Markers (preclin) * Tnf-a Mcp1 0 0.5 1.0 1.5 2.0 * Vcam-1 Relative expression * % change in LDL/HDL Ratio Improved Cholesterol Profile 0,00 5,00 10,00 15,00 20,00 25,00 30,00 35,00 Placebo 15 mg 20 mg GLP1 pmol/L * * Decreased Insulin Resistance Rudling et al. BMC Cardi

  39. Slide 39: Significant NAS Reduction with A4250 in Validated Preclinical STAM Model

    Significant NAS Reduction with A4250 in Validated Preclinical STAM™ Model Matches Prior Findings with Obeticholic Acid OCA Significantly Reduces NAS in Phase 2 study 25 mg OCA or placebo for 72 weeks OCA reduced NAS, fibrosis and liver enzymes, increased cholesterol and pruritus OCA data Kremoser et

  40. Slide 40: SBIODEL Albireo<

    SBIODEL Albireo<

  41. Slide 41: Pediatric Orphan Opportunities Provide Foundation for Albireo Thesis

    Pediatric Orphan Opportunities Provide Foundation for Albireo Thesis Primary Focus Elobixibat partnering in Japan provides potential nondilutive capital to support programs A4250 Novel, First-in-Class Product Candidate to Treat Multiple Pediatric Orphan Liver Diseases with No Approved Drug Options P

  42. Slide 42: Strong Patent and Regulatory Protections

    Strong Patent and Regulatory Protections *H-W PTE for one patent per product A4250 US Expiry Est. H-W PTE* + Ped. Exclusivity Composition of Matter September 2022 2025 MOU IBAT inhibitors to treat liver diseases (pending) November 2031 2033 MOU IBAT inhibitors in combination with bile acid binders t

  43. Slide 43: Significant News Flow and Near-Term Milestones

    Significant News Flow and Near-Term Milestones Projected Event Projected Timing A4250: report additional pediatric data from ongoing Ph2 trial Q4 2016 A4250: FDA meeting (pre-Ph3) Q4 2016 Elobixibat: report data from ongoing Ph3 Trial in Japan 2H 2016 Elobixibat: JNDA filing Q1 2017 A4250: report da

  44. Slide 44: Albireo: Innovative Science + Deep Pipeline + Experienced Management

    Albireo Innovative Science + Deep Pipeline + Experienced Management Leader in the development of bile acid modulators to treat liver and GI diseases Three clinical assets (lead Ph2 orphan and Ph3 constipation product candidates) Multiple near-term inflection opportunities Funding expected to be suff

  45. Slide 45: Thank you

    Thank you NASDAQ: BIOD │ September 21, 2016

Biodel — Merger or Acquisition (September 2016) on 6ix